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Abstract
Background:  NKX3.1  and  PCAN1  are both prostate-specific genes related to prostate
development and prostate cancer. So far, little is known about the regulatory mechanisms of the
expression of these two genes. In the present study, we found that NKX3.1 upregulated PCAN1
gene transcription in LNCaP prostate cancer cells. To understand the regulatory mechanisms, our
work focused on identifying the functional NKX3.1 binding sites upstream of the PCAN1 gene,
which might be involved in the positive regulation of PCAN1 expression by NKX3.1.
Results: We cloned and characterized a 2.6 kb fragment upstream of the PCAN1 gene. Analysis of
the 2.6 kb sequence with MatInspector 2.2 revealed five potential binding sites of NKX3.1
transcription factor. Luciferase reporter assays, electrophoretic mobility shift assays, chromatin
immunoprecipitation and RNA interference were performed to study the effects of NKX3.1 on
PCAN1 gene expression in prostate cancer cells. Our results showed that PCAN1 promoter activity
and mRNA expression were increased by transfection with the NKX3.1  containing plasmid
(pcDNA3.1-NKX3.1) and that PCAN1 mRNA expression was decreased by RNA interference
targeting human NKX3.1 in LNCaP prostate cancer cells. The results of electrophoretic mobility
shift assays and chromatin immunoprecipitation showed that NKX3.1 bound to NBS1 (-1848 to -
1836) and NBS3 (-803 to -791) upstream of the PCAN1 gene. The luciferase reporter assays
showed that NBS1 and NBS3 enhanced the promoter activity in pGL3-promoter vector with
cotransfection of the NKX3.1 containing plasmid. Furthermore, the deletion of NBS1 or both NBS1
and NBS3 reduced PCAN1  promoter activity and abolished the positive regulation of PCAN1
expression by NKX3.1.
Conclusion: Our results suggested that two functional NKX3.1 binding sites located at -1848 to
-1836 and -803 to -791 upstream of the PCAN1 gene were involved in the positive regulation of
PCAN1 gene transcription by NKX3.1.
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Background
Prostate cancer is the most frequently diagnosed neopla-
sia in men and one of the leading causes of cancer-related
deaths in men over 60 [1]. Although early prostate specific
antigen (PSA) detection and surgery have decreased the
death rate, most of the patients still die of metastasis and
recurrence of prostate cancer [2,3]. However, the mecha-
nisms involved in the onset and progression of prostate
cancer are poorly understood at the molecular level. It is
important to understand the molecular biology of this
cancer for its prevention, early diagnosis, and effective
treatment.
PCAN1 (prostate cancer gene 1, also known as GDEP) is
highly expressed in prostate epithelial tissue and fre-
quently mutated in prostate tumors [4-6]. PCAN1 expres-
sion is undetectable in the highly undifferentiated DU145
and PC-3 prostate cancer cell lines and weakly detected in
the more differentiated LNCaP cell line [5]. This gene is
localized to chromosome 4q21, a region of the genome
that experiences frequent loss of heterozygosity (LOH) in
prostate cancer. It is mutated in 35% of the tumor samples
[5]. Therefore,PCAN1 has been proposed to have tumor
suppressing function in prostate cancer.
NKX3.1  is a prostate-specific homeobox gene that is
thought to play an important role in the normal develop-
ment of prostate and carcinogenesis. In mice Nkx3.1 is
exclusively expressed in prostate epithelium [7,8]. Its tar-
geted disruption leads to aberrations in prostate ductal
morphogenesis and secretory protein production, and
epithelial hyperplasia and dysplasia [9]. Notably Nkx3.1
mutant mice display the pathologic changes of prostatic
intraepithelial neoplasia (PIN) [10] that is the presumed
precursor to prostate cancer in humans, implying that loss
of Nkx3.1 expression correlates with the initiation of pros-
tate carcinogenesis. Human NKX3.1 has been mapped to
human chromosome 8p21, a region with frequent loss of
heterozygosity in human prostate cancer [11]. This gene
has been proposed to have tumor suppressing function
[12]. It also inhibits the growth of cultured prostate cancer
cells [13-15] in vitro. The strong association of NKX3.1
with prostate development and prostate cancer makes this
gene an attractive molecular target for further study.
NKX3.1  and  PCAN1  are both prostate-specific genes
strongly related to prostate development and prostate can-
cer. Studying the regulatory mechanisms of their expres-
sion is important for understanding their roles in prostate
development and prostate cancer. In this study, we cloned
and characterized a 2.6 kb fragment upstream of the
PCAN1 gene. Analysis of the 2.6 kb sequence with MatIn-
spector 2.2 revealed potential binding sites of some
important transcription factors, including NKX3.1, P53,
Sp1, cEBP and PPAR/RXR heterodimers. In our study, the
eukaryotic expression plasmids containing NKX3.1, p53,
Sp1, cEBPα and PPARγ were respectively used to study
their effects on PCAN1 expression. We found that NKX3.1
upregulated PCAN1 promoter activity and mRNA expres-
sion. To explore the regulatory mechanisms of NKX3.1 on
PCAN1 transcription, we focused on identifying the func-
tional NKX3.1 binding sites (NBSs) upstream of the
PCAN1 gene. We demonstrated that NKX3.1 upregulated
PCAN1  gene transcription through direct binding with
NBSs upstream of the PCAN1 gene. Our study provided a
molecular mechanism for the regulation of PCAN1 gene
expression.
Results
Effects of NKX3.1 on PCAN1 promoter activity and 
mRNA expression
In our previous work, a 2.6 kb promoter fragment (+32 to
-2598) of the PCAN1 gene amplified by PCR was inserted
into pGL3-basic vector to form the PCAN1 promoter-luci-
ferase reporter plasmid designated as pGL3-pPCAN1. Fire-
fly luciferase expression driven by the 2.6 kb PCAN1
promoter was used to evaluate the promoter activity [16].
To detect the effects of NKX3.1 on PCAN1 gene expres-
sion, LNCaP and PC-3 cells were harvested 48 h after
cotransfection with pGL3-pPCAN1 and pcDNA3.1-
NKX3.1. The control cells were cotransfected with pGL3-
pPCAN1 and pcDNA3.1 (+) plasmid. The PCAN1  pro-
moter activity detected by dual-luciferase reporter assays
was enhanced by 1.6-fold in LNCaP cells and by 1.8-fold
in PC-3 cells with NKX3.1 cotransfection, compared with
PCAN1 promoter activity in the control cells (Fig. 1).
Effects of NKX3.1 on the PCAN1 promoter in LNCaP and  PC-3 cells Figure 1
Effects of NKX3.1 on the PCAN1 promoter in LNCaP and PC-3 cells. 
LNCaP and PC-3 cells were cotransfected with pGL3-pPCAN1 and pcDNA3.1-
NKX3.1 (grey bars). The control cells were cotransfected with pGL3-pPCAN1 and 
pcDNA3.1 (+) plasmid (blank bars). The cells were harvested 48 h after transfection 
and PCAN1 promoter activity was detected by dual-luciferase reporter assays. Results 
were expressed as relative luciferase activities (M1/M2). The data were represented 
as the mean of four individual values ± SD.*p < 0.05, **p < 0.05, grey bar vs blank bar.BMC Molecular Biology 2008, 9:45 http://www.biomedcentral.com/1471-2199/9/45
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The PCAN1 mRNA expression level in LNCaP cells, as
detected by RT-PCR, was increased significantly by
NKX3.1 cotransfection, compared with that of the control
cells transfected with pcDNA3.1 (+) plasmid (Fig. 2A and
2B). The PCAN1 mRNA expression level in PC-3 cells was
undetectable by RT-PCR (Fig. 2A and 2B).
The expression of endogenous NKX3.1 in LNCaP cells was
knocked down by RNAi, which made the PCAN1 mRNA
expression decrease, as detected by RT-PCR (Fig. 2D).
Identification of specific NKX3.1 binding sites (NBSs) with 
nuclear extracts
Analysis of the 2.6 kb promoter sequence with MatInspec-
tor 2.2 revealed five potential NKX3.1 transcription factor
binding sites (sequences are shown in Fig. 3A). They were
located at -1848 to -1836 (NBS1), -1080 to 1068 (NBS2),
-803 to -791 (NBS3), -179 to 166 (NBS4) and -131 to -
119 (NBS5), upstream of the PCAN1 gene. To investigate
the binding activities of these five NBSs with NKX3.1 tran-
scription factor, we carried out electrophoretic mobility
shift assays (EMSA). It was performed with NKX3.1-trans-
fected nuclear extracts from LNCaP cells and synthesized
oligonucleotide probes containing these five NBS
sequences. The results showed that DNA-protein binding
complexes were identified for the NBS1 probe and the
NBS3 probe (Fig 3B). The bindings of NBS1 and NBS3
with nuclear extracts proved to be specific, as they were
blocked by a 250-fold excess of unlabeled NBS1 probe
(Fig. 3C) or NBS3 probe (Fig. 3D) and by anti-NKX3.1
antibody (Fig. 3C and 3D), but not by unlabeled mutant
NBS1 probe or mutant NBS3 probe (Fig. 3C and 3D).
NKX3.1 binds to NBS1 and NBS3 upstream of the PCAN1 
gene in living cells
To determine whether NKX3.1 also binds to the NBSs in
vivo, we performed chromatin immunoprecipitation
(ChIP) assays, which are used to define interactions of
proteins with specific DNA elements in living cells. ChIP
was carried out in LNCaP cells transfected with
pcDNA3.1-NKX3.1. After cross-linking with formalde-
hyde, cell lysates were immunoprecipitated with anti-
NKX3.1 antibody or rabbit IgG (negative control). The
DNA purified from this coprecipitation was analyzed by
PCR with primers (sequences are shown in Table 1) span-
ning the NBSs in the PCAN1 promoter. As shown in Fig.
4, we observed a clear PCR product using NBS1 primer or
NBS3 primer but no band was observed using NBS2
primer or NBS4,5 primer, and no PCR product was iden-
tified for all primers with rabbit IgG precipitation com-
plexes, indicating that NKX3.1 bound to NBS1 and NBS3
upstream of the PCAN1 gene in living cells.
Effects of NKX3.1 on PCAN1 mRNA expression in LNCaP  and PC-3 cells Figure 2
Effects of NKX3.1 on PCAN1 mRNA expression in 
LNCaP and PC-3 cells. The effects of NKX3.1 on PCAN1 
mRNA expression as detected by RT-PCR. A. PCAN1 mRNA 
expression following transfection of LNCaP cells with 1. 
pcDNA3.1-NKX3.1; 2. pcDNA3.1 (+); or following transfec-
tion of PC-3 cells with 3. pcDNA3.1-NKX3.1; or 4. 
pcDNA3.1 (+). B. Relative expression levels were presented 
as the ratio of densities of NKX3.1 or PCAN1 to β-actin 
bands. The results were expressed as mean ± SD (n = 3). C. 
The expression of NKX3.1 protein in LNCaP and PC-3 cells 
after transfection of pcDNA3.1-NKX3.1 (1, 3, 5, 7) or 
pcDNA3.1 (+) (2, 4, 6, 8).D. NKX3.1 and PCAN1 mRNA 
expression following stable transfection of LNCaP cells with 
1. pRNAT-RNAi1 targeting human NKX3.1; 2. pRNAT-RiN 
as a control vector.BMC Molecular Biology 2008, 9:45 http://www.biomedcentral.com/1471-2199/9/45
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Interaction of NKX3.1 with NBS1 or NBS3 stimulates 
luciferase reporter expression driven by SV40 promoter
To investigate the interactions between NKX3.1 and these
five potential NBSs in vivo, five pGL3-NBS-promoter luci-
ferase plasmids were constructed (Fig. 5) and cotrans-
fected with pcDNA3.1-NKX3.1 plasmid respectively into
LNCaP cells, while the control cells were cotransfected
with pcDNA3.1 (+) vector. The luciferase reporter assays
showed that when cotransfected with NKX3.1 expression
plasmid, NBS1 and NBS3 enhanced SV40 promoter activ-
ity by 1.7-fold and 2.1-fold, respectively, compared with
that of the control cells that were cotransfected with
pcDNA3.1 (+) vector. NBS2, NBS4, NBS5 showed no sig-
nificant effects on SV40 promoter activity. These results
suggested that NBS1 and NBS3 were the functional cis-ele-
ments in vivo for the upregulation by NKX3.1.
Deletion of NBS1 and NBS3 in the PCAN1 promoter 
abolishes the positive regulation by NKX3.1
The binding assays of five NBSs in vivo and in vitro sug-
gested that NBS1 and NBS3 in the PCAN1 promoter were
involved in the positive regulation of PCAN1 expression
by NKX3.1. To further confirm this observation, the
sequences of NBS1, or both NBS1 and NBS3 were deleted
from pGL3-pPCAN1 to examine the effects of the deletions
on PCAN1 promoter activity. The results in Fig. 6 showed
that deletion of NBS1 (pGL3-NBS1id-pPCAN1) or both
NBS1 and NBS3 (pGL3-NBS1,3idd-pPCAN1) reduced the
promoter activity to 75% or 50% of the wild-type pro-
moter (pGL3-pPCAN1). With cotransfection of the
NKX3.1 expression plasmid, deletion of NBS1 partially
abolished, and deletion of both NBS1 and NBS3 com-
pletely abolished NKX3.1 stimulation of the PCAN1 pro-
moter. These findings suggested that NBS1 and NBS3
upstream of the PCAN1 gene were functional cis-elements
mediating the positive regulation by NKX3.1 of PCAN1
gene transcription.
Discussion
NKX3.1  is a prostate-specific homeobox gene that is
thought to play important roles in normal prostate devel-
opment. NKX3.1 protein has been proposed to act as a
specific tumor suppressor in prostate. Loss of NKX3.1
expression correlates with prostate carcinogenesis [15]
and prostate tumor progression [17]. It was reported that
NKX3.1 could collaborate with other transcription factors,
Binding assays of NKX3.1 binding sites with nuclear extracts Figure 3
Binding assays of NKX3.1 binding sites with nuclear extracts. A. Locations and sequences of five potential NKX3.1 
binding sites (NBSs) upstream of the PCAN1 gene. B. EMSA was performed to assay the binding activities of the five NBSs with 
the nuclear extracts from LNCaP cells. 1–5: labelled NBS1~NBS5 with LNCaP nuclear extracts respectively. A DNA-protein 
binding complex was formed when the labelled probe of NBS1 (lane 1) or NBS3 (lane 3) was reacted with LNCaP nuclear 
extracts. C and D. Competition binding and antibody blocking were used to detect the specific binding of the NBS1 (C) or 
NBS3 (D) with NKX3.1. Labelled NBS1 or NBS3 without nuclear extracts was used as the control (lane1); a specific DNA-pro-
tein complex was formed when labelled NBS1 or NBS3 was reacted with LNCaP nuclear extracts (lane 2). Competition bind-
ing was performed in the presence of a 250-fold molar excess of unlabelled NBS1 or NBS3 (lane 3), unlabelled mutant NBS1 or 
NBS3 (lane 4). The binding activity of probe NBS1 or NBS3 to nuclear extracts could be blocked by anti-NKX3.1 antibody 
(lane5).BMC Molecular Biology 2008, 9:45 http://www.biomedcentral.com/1471-2199/9/45
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such as serum response factor (SRF) [18], Sp-family pro-
tein [19] and prostate derived Ets factor (PDEF) [20], to
regulate the expression of target genes. The potential for
NKX3.1 to exert a differentiating and growth suppressing
effect on prostatic epithelium was confirmed by targeted
gene disruption of Nkx3.1 in mice [21]. Deletion of either
one or both copies of Nkx3.1 resulted in prostatic epithe-
lial hyperplasia and dysplasia that increased in severity
with age. Magee et al. [21] has analyzed the expression
profiles of prostate tissues from wild-type,Nkx3.1+/-, and
Nkx3.1-/- mice and identified Nkx3.1 target genes. How-
ever, the genes directly regulated by human NKX3.1 have
yet to be identified. In the present study, we found that
NKX3.1 upregulated the expression of the PCAN1 gene in
LNCaP prostate cancer cells and identified two functional
NKX3.1 binding sites upstream of the PCAN1 gene.
PCAN1  is highly expressed in prostate epithelial tissue
and was initially identified in a screen for prostate-specific
genes. As an important gene in prostate cancer initiation
or progression [22], it has been shown that PCAN1 is fre-
quently mutated or deleted in prostate tumor samples [5]
and differentially expressed in tumor versus normal pros-
tate tissue, demonstrating a prostate tumor suppressor
role [6]. So far, little is known about the regulatory mech-
anisms of PCAN1 gene expression as well as the relevant
regulatory elements and factors. Cross et al. [4] has iden-
tified PCAN1 gene in prostate epithelial tissue and dem-
onstrated its expression pattern in different cells. They did
an initial characterization of 2.5 kb sequence upstream of
the initiation sites with the MatInspector program, in
which they found several important transcription factor
binding sites, including NKX3.1 binding sites. In our
study, we cloned a 2.6 kb PCAN1 promoter sequence and
five NKX3.1 binding sites were found in this region with
the MatInspector (core/matrix sim: 0.75/optimized). We
further performed reporter assays, RNAi, EMSA and ChIP
to demonstrate that NKX3.1 could directly bind to
NKX3.1 binding sites in the PCAN1 promoter to enhance
PCAN1 gene expression in prostate cancer cells. This find-
ing provides a foundation for future studies of the regula-
tory mechanisms and roles of NKX3.1 on PCAN1 gene
expression in prostate development and prostate cancer.
NKX3.1 is proposed to be a nuclear transcriptional factor.
It preferentially binds the TAAGTA sequence [23] to regu-
late its target gene expression. It is reported that NKX3.1
NKX3.1 binds to the NBSs of the PCAN1 promoter in living  cells Figure 4
NKX3.1 binds to the NBSs of the PCAN1 promoter in 
living cells. LNCaP cells transfected with pcDNA3.1-
NKX3.1 were cross-linked by formaldehyde treatment and 
lysed. Cell lysates were subjected to immunoprecipitation 
with either an antibody to NKX3.1 (A) or rabbit IgG (B). 
Four primers (names and sequences are shown in Table 1) 
spanning five NBSs of PCAN1 promoter region were used for 
PCR of recovered DNA from the immunoprecipitation 
(lanes 2–5). Input DNA was used as positive control (C).
Table 1: PCR primers used in chromatin immunoprecipitation
Names Sequences Product sizes
NBS1 primers F: GATTCTTTGACTGGTCTGGCACAC
R: TTATCCATTGTGCCTGGAGCTGAG 170 bp (spanning NBS1)
BNS2 primers F: TCCTACTAACGGCATGTAAGGAGG
R: ATTGCCATGTCTGGACTGTGAGTG 170 bp (spanning NBS2)
NBS3 primers F: AAGAATGAGCTGATCCTCCTATGC
R: GGTTTAGTAATAGACTGGGCACCA 150 bp (spanning NBS3)
NBS4,5 primers F: GTGTAGCAGGTAAATCAGTGTGAG
R: TCAGCTGACGAGCAACTTCAATTC 180 bp (spanning NBS4 and 5)
NBS1 F and R span NBS1;
NBS2 F and R span NBS2; NBS3 F and R span NBS3; BNS4,5 F and R span NBS4 and NBS5BMC Molecular Biology 2008, 9:45 http://www.biomedcentral.com/1471-2199/9/45
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acts as a transcription factor through recruitment of some
corepressors [24,25] or coactivators [26,27] to repress or
activate its target genes. Our study provided some evi-
dences to show that NKX3.1 directly binds to NKX3.1
binding sites in the PCAN1 promoter to activate PCAN1
gene expression in prostate cancer cells. However, further
studies will be required to explore the regulatory mecha-
nisms and the cofactors involved in the regulation.
NKX3.1 is a prostate-specific gene required for mainte-
nance of the normal differentiated state of the prostate
epithelium. It is proposed to have tumor suppressing
function. However, it is not a classic tumor suppressor
gene. Despite that loss of function of NKX3.1 predisposes
to prostate cancer, it is not sufficient for tumorigenesis.
Moreover, while one allele of NKX3.1 is lost by means of
chromosomal deletion in prostate cancer, the other allele
does not undergo mutational inactivation. These features
are not consistent with activities of "classic" tumor sup-
pressor genes. Instead, NKX3.1 appears to act more like a
tumor modulator, serving as a regulator of differentiation,
which in turn prevents cancer initiation. Our finding that
NKX3.1 upregulates PCAN1 expression will give a clue for
further exploring the relationships between NKX3.1 and
PCAN1 and understanding the functional importance of
NXK3.1 in regulating PCAN1 in prostate differentiation
and carcinogenesis. Identification of the specific biologi-
cal functions of NKX3.1 in prostate cancer may provide
targets for the early diagnosis and prevention of prostate
cancer.
NKX3.1 is an androgen regulated gene and its expression
is upregulated by androgens. It is presumed that andro-
gens upregulate PCAN1  expression through increasing
NKX3.1 expression. In the experiments we have analyzed
the effect of androgen (R1881) on endogenous PCAN1
and  NKX3.1  expression in LNCaP cells. Our results
showed that R1881 (10-8~10-10  M) increased NKX3.1
expression but have no significant effects on PCAN1
expression in RT-PCR (results are not shown in this paper)
and PCAN1 promoter activity in luciferase reporter assays
(results are shown in our paper in Cell Mol Biol Lett). So
far, it is not very clear whether or not PCAN1 gene expres-
sion is regulated directly by androgens. It may be possible
that  PCAN1  is negatively regulated by androgens and
NKX3.1 compensates this effect through positively regu-
lating PCAN1. In addition, AR, NKX3.1 and PCAN1 play
different roles in prostate development and cancer, and
their interactions in prostate are very complicated and
need further to be investigated.
Conclusion
In conclusion, we cloned and characterized the human
PCAN1 promoter, and identified two functional NKX3.1
binding sites upstream of the PCAN1 gene, which were
involved in the positive regulation by NKX3.1 of PCAN1
Effects of deletion of NBS1 and NBS3 on PCAN1 promoter  activity Figure 6
Effects of deletion of NBS1 and NBS3 on PCAN1 pro-
moter activity. pGL3-pPCAN1 is a luciferase reporter plas-
mid containing a 2.6 kb wild type PCAN1 promoter; pGL3-
NBS-Id represented pGL3-NBS1id-pPCAN1 with deletion of 
NBS1 from the PCAN1 promoter; pGL3-NBS-Idd represented 
pGL3-NBS1,3idd-pPCAN1, in which both NBS1 and NBS3 
were deleted from the PCAN1 promoter. They were cotrans-
fected with pcDNA3.1-NKX3.1 (grey bar) or pcDNA3.1 (+) 
vector (blank bar) into LNCaP cells, and the promoter activ-
ity was analyzed by dual-luciferase reporter assays. Results 
were expressed as relative luciferase activities (M1/M2). The 
data were represented as the mean of four individual values 
± SD. *p < 0.01, **p < 0.05, grey bar vs blank bar.
Effects of NBSs on the SV40 heterogeneous promoter Figure 5
Effects of NBSs on the SV40 heterogeneous pro-
moter. The sequences of five NBSs were synthesized in vitro 
and inserted upstream of the SV40 promoter in pGL3-pro-
moter vector generating the pGL3-NBS-promoter plasmids. 
The five recombinant pGL3-NBS-promoter plasmids or 
pGL3-promoter vector were then cotransfected with 
pcDNA3.1-NKX3.1 respectively, to study the effects of NBSs 
on the activity of the SV40 heterogeneous promoter. 
Cotransfection of pGL3-NBS-promoter with pcDNA3.1 (+) 
vector was used as the control. The promoter activities 
were determined by dual luciferase assays. Results were 
expressed as relative luciferase activity (M1/M2). The data 
were represented as the mean of four individual values ± SD. 
*p < 0.01,**p < 0.01, strip bar vs blank bar.BMC Molecular Biology 2008, 9:45 http://www.biomedcentral.com/1471-2199/9/45
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gene expression. Both NKX3.1 and PCAN1 are related to
prostate development and prostate cancer. Our findings
will contribute to the understanding of molecular regula-
tory mechanisms of PCAN1 gene expression in prostate
development and cancer.
Methods
Construction of the NKX3.1 eukaryotic expression 
plasmid (pcDNA3.1-NKX3.1)
pCR2.1-NKX3.1, a T-clone of NKX3.1 cDNA containing
the complete sequence of NKX3.1 (a gift from Dr. Charles
Young, Mayo Clinics, USA), was digested with EcoR  I
(TakaRa, Shiga, Japan) to release the 971 bp fragment of
NKX3.1  cDNA. The NKX3.1  cDNA sequence (971 bp)
contains the CDS of NKX3.1 including a start codon, a
stop codon and a partial 3' UTR. It was then inserted into
pcDNA3.1 (+) vector (Invitrogen Life Technologies, San
Diego, CA, USA), which had been digested with EcoR I
and dephosphorylated with calf intestine alkaline phos-
phatase (TaKaRa), to generate the NKX3.1-cDNA eukary-
otic expression plasmid pcDNA3.1-NKX3.1. The
recombinant plasmid was digested with EcoR I to identify
the size of the insert and digested with Not I (TaKaRa) to
identify the correct insert orientation. The NKX3.1 cDNA
was also confirmed by DNA sequencing.
Construction of the PCAN1 promoter-luciferase reporter 
plasmid (pGL3-pPCAN1)
The 2.6 kb promoter fragment (+32 to -2598) of the
PCAN1 gene was amplified by PCR using human genomic
DNA as the template. The primer pairs were PCANF 5'-
CCCTAGCTAGCCATCTCTGCAGTCTCGAC-3' with a Nhe
I site at the 5'-end and PCANR 5'-CCCAAGCTTCGCTCT-
GACTTCCTCTTC-3' with a Hind III site at the 5'-end. The
PCR was conducted at 96°C for 2 min followed by 35
cycles at 98°C for 20 s, 68°C for 10 min. The amplified
fragment was isolated and purified following agarose elec-
trophoresis using a Gel Extract Kit (Omega Bil-Tek. Inc.
Doraville, GA, USA), digested with Nhe I and Hind III
(TaKaRa), and ligated into the equivalent sites of the
pGL3-basic vector (Promega, Madison, WI, USA) to gener-
ate the pGL3-pPCAN1 construct. The resulting construct
was confirmed by restriction enzyme digestion and DNA
sequence analysis.
Construction of luciferase reporter plasmids of NKX3.1 
binding sites (pGL3-NBS-promoter)
Analysis of the 2.6 kb promoter sequence using MatIn-
spector 2.2 revealed five potential binding sites for the
NKX3.1 transcription factor. To confirm the functional
binding sites, we synthesized oligonucleotides corre-
sponding to these five sequences (NBS1~NBS5) shown in
Table 2. Each NBS sequence was synthesized with an over-
hanging Mlu I site (CGCGT) at the 5'-end of the sense
strand and an overhanging Xho I site (TCGAG) at the 5'-
end of the antisense strand. The double-stranded NBS was
generated by annealing equal amounts of sense and anti-
sense oligonucleotides at 95°C for 10 min, then cooling
to room temperature. The double-stranded NBS was
inserted upstream of the SV40 promoter in the pGL3-pro-
moter (Promega) vector to generate the recombinant plas-
mid of NBS-SV40 promoter-luciferase reporter gene. All
constructs were confirmed by DNA sequencing.
Construction of the NBS deletion plasmids of pGL3-
pPCAN1
The construction of NBS1 or both NBS1 and NBS3 dele-
tion plasmids was made by a two-step PCR procedure. In
the first step, pGL3-pPCAN1 was used as the template for
the construction of pGL3-NBS1id-pPCAN1, and two PCR
fragments were generated with two primer pairs, NBS1id-
up 5'-CCCTGACTTGGGGGGCTCC ACTGTAGTAC-3' and
PCANF 5'-CCCTAGCTAGCCATCTCTGCAGTCTCGAC-3',
NBS1id-down 5'-TGGAGCCCCCCAAGTCAGGGGGTT-
TAATC-3' and PCANR 5'-CCCAAGCTTCGCTCTGACTTC-
CTCTTC-3'. The PCR conditions were 94°C for 2 min,
98°C for 10 s, 68°C for 5 min, 32 cycles. The two PCR
fragments were purified by agarose electrophoresis and
used together as templates in the second step of PCR with
primers PCANF and PCANR. The PCR conditions were
94°C for 2 min, 60°C for 30 s, 72°C for 5 min, followed
by addition of PCANF and PCANR primers and PCR at
98°C for 10 s, 68°C for 6 min, 32 cycles. The PCR frag-
ments and pGL3-basic were both digested with Hind III
and Nhe I and ligated together to construct pGL3-NBS1id-
pPCAN1. A similar approach was used to generate pGL3-
NBS1, 3idd-pPCAN1, in which both NBS1 and NBS3
sequences were deleted. pGL3-NBS1id-pPCAN1 was used
as the template and other two primer pairs, NBS3id-up 5'-
GAATGCCTGGTATTTCTTATCAAGAGAAC-3' and
PCANF, NBS3id-down 5'-ATAAGAAATACCAGGCATTC-
CCTTCCACCA-3' and PCANR, were used. The constructed
deletion plasmids were validated by DNA sequencing.
Cell culture
The human prostate cancer cell lines LNCaP and PC-3
were obtained from the American Type Culture Collection
(ATCC). They were grown at 37°C in 5% CO2 with RPMI
Table 2: Probes used in electrophoretic mobility shift assays
Names Sequences (sense strand)
NBS1 GATTAAGTCTACT
NBS2 AGGTAAGTAAAG
NBS3 AAATAAGTAGCCT
NBS4 CAATAAGTTTTAT
NBS5 TGTTAAGTATCCT
Mutant NBS1 GATTCCTGCTACT
Mutant NBS3 AAATCCTGAGCCTBMC Molecular Biology 2008, 9:45 http://www.biomedcentral.com/1471-2199/9/45
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1640 media (Sigma, St. Louis, MO, USA) supplemented
with 10% fetal bovine serum (Gibco, BRL Grand Island,
NK, USA), ampicillin 100 U/ml and streptomycin 100 U/
ml.
Transient transfection
For the promoter activity assay of pGL3-pPCAN1, LNCaP
and PC-3 cells were transfected with lipofectamin™ 2000
(Invitrogen) in 24-well plates. Each well included 1.5 ×
105 cells, 1.0 µg pGL3-pPCAN1, 0.04 µg internal control
vector pRL-TK (Promega), 2 µl lipofectamin™ 2000 and
500 µl RPMI 1640 media without serum and antibiotics.
The cells were analyzed using a dual-luciferase reporter
assay system (Promega) 48 h after completion of the
transfection procedure.
For cotransfection experiments of the NKX3.1 expression
plasmid (pcDNA3.1-NKX3.1) with pGL3-construct (pGL3-
pPCAN1, pGL3-NBS-promoter, pGL3-NBS1id-pPCAN1 or
pGL3-NBS1,3idd-pPCAN1), LNCaP cells were transfected
with lipofectamin™ 2000 in 24-well plates, and each well
included 1.5 × 105 cells, 0.8 µg pGL3-construct, 0.4 µg
pcDNA3.1-NKX3.1, 0.04 µg pRL-TK, 2 µl lipofectamin™
2000 and 500 µl RPMI 1640 media without serum and
antibiotics.
Dual-luciferase reporter assays
Forty-eight hours after the transfection, the activities of
Firefly luciferase in pGL3-constructs and Renilla luciferase
in pRL-TK were determined by the dual-luciferase reporter
assays following the protocol of the manufacture
(Promega). The cells were rinsed with phosphate-buffered
saline, and lysed with 1 × passive lysis buffer. Twenty µl of
cell lysate was transferred into the luminometer tube con-
taining 100 µl luciferase assay reagent II. Firefly luciferase
activity (M1) was measured first, and then Renilla luci-
ferase activity (M2) was determined after the addition of
100 µl Stop & Glo reagent. M1/M2 was taken as the rela-
tive luciferase activity of the pGL3-constructs.
Reverse transcription-PCR
Total RNA was isolated from LNCaP and PC-3 cells using
Trizol reagent (Invitrogen) 48 h after transfection with
pcDNA3.1-NKX3.1, and expression of PCAN1 mRNA was
determined by RT-PCR with M-MuL V reverse tran-
scriptase (Promega) in the presence of random hexamer
primers. PCR primers for PCAN1 were PCAN-F 5'-GCGAT-
GTGCTGTGAAATCTA-3',  PCAN-R 5'-CTTTCACATTC-
CCCGTGGT-3'; for NKX3,1  were  NKX-F 5'-
GTACCTGTCGGCCCCTGAACG-3',  NKX-R 5'-GCTGT-
TATACACGGAGACCAGG-3'. A β-actin mRNA was ampli-
fied and used to normalize the quantity of the PCAN1
mRNA in RT-PCR. The primers were β-actinF 5'-GCTGT-
CAGAGTGGTTATGT-3',  β-actinR 5'-ACATTGACGTACA-
GAG AGAG-3'. The PCR conditions were 94°C 3 min,
94°C 30 s, 56°C 30 s for PCAN1, 63°C 30 s for NKX3.1,
72°C 50s, 32 cycles for PCAN1, 26 cycles for NKX3.1,
72°C 6 min. The products were identified by 1.5% agar-
ose gel electrophoresis.
Western blot analysis of NKX3.1 protein expression
Expression of NKX3.1 in prostate cancer cells was ana-
lyzed by Western blot analysis. Briefly, total protein was
extracted from PC-3 cells or LNCaP cells using lysis buffer
(containing 50 mM Tris-Cl, pH 8.0, 150 mM NaCl,
0.1%SDS, 1%NP-40, 100 µg/ml PMSF) after transfection
with pcDNA3.1-NKX3.1 for 48 h to 72 h. The protein con-
tent of the samples was measured using the BCA protein
assay kit (Shenergy Biocolor Bioscience & Technology
Company, Shanghai, China). Thirty µg of each protein
sample was used to detect the NKX3.1 protein expression
by Western blot analysis. The primary antibody was rabbit
anti-human NKX3.1 (RDI, Concord MA, USA) diluted 1:
2000; the second antibody was goat anti-rabbit IgG
(Sigma) diluted 1: 2000. Relative protein levels were cal-
culated in comparison to β-actin as standard. Immunob-
lots were detected using an ECL kit (Santa Cruz, CA, USA)
and visualized after exposure to X-ray film.
Electrophoretic mobility shift assays (EMSA)
Nuclear extracts were prepared from LNCaP cells using a
nuclear extraction kit (Active Motif, Carlsbad, CA, USA)
following the manufacturer's instructions. Oligonucle-
otides corresponding to the five binding sites shown in
Table 2 were synthesized as probes. Equal amounts of
sense and antisense oligonucleotides of NBSs were mixed
and annealed in a buffer (10 mM Tris-HCl, pH 8.0, 200
mM NaCl, 1 mM EDTA) by heating to 95°C for 5 min and
cooling slowly to room temperature. The five double-
stranded NBSs were labelled with digoxigenin (DIG)
(Roche). Binding reactions were performed for 20 min at
room temperature in a 20 µl mixture containing 0.2% (W/
V) Tween-20, 1 mM EDTA, 1 mM dithiothreitol, 30 mM
KCl, 20 mM HEPES (pH 7.6), 1 µg of poly (dI-dC), 0.1 µg
of poly (L-Lys), 20 µg of nuclear extract and 0.8 ng of DIG
labelled double-stranded NBS. For the competition exper-
iment, unlabelled double-stranded NBS or mutant NBS
(sequences are shown in Table 2) in 250-fold excess were
added to the binding reaction mixture and incubated. For
supershift assays, anti-NKX3.1 antibody was pre-incu-
bated with the nuclear extracts at room temperature for 30
min in the binding buffer, followed by an additional incu-
bation for 20 min at room temperature with the reaction
mixtures. Bound and free oligonucleotide probes were
resolved by electrophoresis on an 8% nondenaturing
polyacrylamide gel in 0.25 × Tris-Boric acid (TBE) buffer.
Electroblotting and chemiluminescence detection were
performed based on the instructions of the manufacturer
of the DIG gel shift kit (Roche, Penzberg, Germany).BMC Molecular Biology 2008, 9:45 http://www.biomedcentral.com/1471-2199/9/45
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Chromatin immunoprecipitation (ChIP)
In vivo binding of NKX3.1 to the NBSs in the upstream
region of the PCAN1 gene was investigated using the ChIP
assay kit (Upstate Biotechnology, Inc., Lake Placid, NY,
USA). Confluent human LNCaP prostate cancer cells were
transfected with pcDNA3.1-NKX3.1. Forty-eight hours
after the transfection, cells were treated with formalde-
hyde (1% final concentration) to cross-link NKX3.1 to the
DNA. Cells were washed with cold phosphate-buffered
saline and lysed in SDS lysis buffer (1% SDS, 10 mM
EDTA, and 50 mM Tris-HCl pH 8.1). The lysate was soni-
cated to shear DNA to a length between 200 and 1000 bp.
The sonicated supernatant was diluted 10-fold with ChIP
dilution buffer (0.01% SDS, 1% Triton X-100, 2 mM Tris-
HCl pH 8.1), and 150 mM NaCl) and incubated with
anti-NKX3.1 antibody (Santa Cruz) or rabbit IgG over-
night at 4°C with rotation. To collect DNA/protein com-
plexes, salmon sperm DNA/protein A-agarose slurry was
added to the mixture and incubated for 1 h at 4°C with
rotation, and the DNA/protein A-agarose was pelleted by
centrifugation. After extensive washing of the pellet with a
series of wash buffers, the pellet was dissolved with 250 µl
of elution buffer and centrifuged to remove the agarose.
The supernatant was treated with 20 µl of 5 M NaCl and
heated to 65°C for 4 h to reverse the NKX3.1-DNA cross-
link. After treatment with EDTA and proteinase K, the
supernatant was extracted with phenol/chloroform and
precipitated with ethanol to recover the DNA. For PCR
using the chromatin-immunoprecipitated DNA, one-
tenth of the DNA was PCR-amplified using four pairs of
primers (primer names and sequences are shown in Table
1) that span the five NBSs in the upstream region of the
PCAN1  gene respectively. Twenty-five cycles of PCR at
94°C for 30 s, 60°C for 30 s, and 72°C for 30 s were per-
formed. PCR products were analyzed in 1% agarose gels.
RNA interference (RNAi)
pRNAT-U6.1/Neo, containing human U6 promoter, was
used to generate a series of RNAi expression vectors by
inserting annealed oligonucleotides between BamH I and
Hind  III sites. The oligonucleotides RNAi1 (5'GATC-
CCCagttcagccatcagaagtaTT CAAGAGAtacttctgatggctgaactT
TTTTGGAAA3' and 3'GGGtcaagtcggtagtcttcatAA GTTCTC
TatgaagactaccgacttgaAAAAACCTTTTCGA5'), RNAi2
(5'GATCCCCtcca gaacagacgctataaTTCAAGAGAttatagcgtct
gttctggaTTTTTGGAAA3' and 3'GGGagg tcttgtctgcgatattAA
GTTCTCTaatatcgcagacaagacctAAAAACCTTTTCGA5'),
RNAi3 (5'GATCCCCtataacagctatccttactTTCAAGAGAagtaa
ggatagctgttataTTTTTGGAAA3'and 3'GGGatattgtcgataggaa
tgaAAGTTCTCTtcattcctatcgacaatatAAAAACCTTTTC GA5')
were used for the construction of pRNAT-RNAi (1~3) tar-
geting human NKX3.1. The oligonucleotides RiN
(5'GATCCCCttctccgaacgtgtcacgtTTCAAGAGA acgtgacacgtt
cggagaaTTTTTTGGAAA3' and 3' GGGaagaggcttgcacagt-
gcaAAGTTCT CTtgcactgtgcaa
gcctcttAAAAACCTTTTCGA5') were used for a control vec-
tor pRNAT-RiN producing a random sequence of RNAi.
pRNAT-RNAi (1–3) and pRNAT-RiN were transfected into
LNCaP cells, Forty-eight hours post-transfection, the cells
were harvested to detect the silencing of NKX3.1 with RT-
PCR and Western blot. The stable cell lines transfected
with pRNAT-RNAi1 or pRNAT-RiN were selected with
G418 (20 µg/ml) and individual clones were isolated.
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